Mitoxantrone (Novantrone) for Prostate Cancer
|157,012 Patients Studied||263 Studies (View)|
Definition: Mitoxantrone is an anthracenedione (not an anthracycline) antineoplastic agent. One of the most common malignant tumors afflicting men. The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland. Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes. Adenocarcinomas represent the overwhelming majority of prostatic carcinomas. Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma. Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy. Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease. (SOURCE: Wikipedia, UMLS)
Where does Mitoxantrone (Novantrone) rank compared to other Prostate Cancer treatments?
Health experts published 311 studies on Estramustine and Prostate Cancer making Estramustine the #21 most researched treatment. In research involving Prostate Cancer, experts have concluded that Estramustine is effective in 51 studies and safe in 49 studies.
Health experts published 261 studies on Prednisone and Prostate Cancer making Prednisone the #22 most researched treatment. In research involving Prostate Cancer, experts have concluded that Prednisone is effective in 26 studies and safe in 15 studies.
What does the FDA say about side effects?
Most Researched Conditions
What other conditions have been studied?
What treatments have patients discontinued using?